Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LLY logo LLY
Upturn stock ratingUpturn stock rating
LLY logo

Eli Lilly and Company (LLY)

Upturn stock ratingUpturn stock rating
$793.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/11/2025: LLY (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

29 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $951.98

1 Year Target Price $951.98

Analysts Price Target For last 52 week
$951.98 Target price
52w Low $675.71
Current$793.01
52w High $967.27

Analysis of Past Performance

Type Stock
Historic Profit 46.8%
Avg. Invested days 60
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/11/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 711.91B USD
Price to earnings Ratio 64.52
1Y Target Price 951.98
Price to earnings Ratio 64.52
1Y Target Price 951.98
Volume (30-day avg) 29
Beta 0.39
52 Weeks Range 675.71 - 967.27
Updated Date 07/11/2025
52 Weeks Range 675.71 - 967.27
Updated Date 07/11/2025
Dividends yield (FY) 0.77%
Basic EPS (TTM) 12.29

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 22.67%
Operating Margin (TTM) 42.49%

Management Effectiveness

Return on Assets (TTM) 16.45%
Return on Equity (TTM) 77.28%

Valuation

Trailing PE 64.52
Forward PE 36.36
Enterprise Value 745089892463
Price to Sales(TTM) 14.53
Enterprise Value 745089892463
Price to Sales(TTM) 14.53
Enterprise Value to Revenue 15.2
Enterprise Value to EBITDA 45.78
Shares Outstanding 897736000
Shares Floating 895500289
Shares Outstanding 897736000
Shares Floating 895500289
Percent Insiders 0.16
Percent Institutions 83.96

ai summary icon Upturn AI SWOT

Eli Lilly and Company

stock logo

Company Overview

overview logo History and Background

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist. It has grown from a small laboratory into a global pharmaceutical leader, pioneering the mass production of penicillin during World War II and developing innovative medicines for diabetes, cancer, and other diseases.

business area logo Core Business Areas

  • Human Pharmaceutical Products: Focuses on the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products. Includes treatments for diabetes, oncology, immunology, neuroscience, and other therapeutic areas.
  • Animal Health: Develops and markets products for companion animals and livestock. This segment focuses on preventing and treating diseases in animals, improving animal health and productivity.

leadership logo Leadership and Structure

David A. Ricks is the Chairman and CEO. The company is structured into global business units focusing on specific therapeutic areas, supported by centralized research and development, manufacturing, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Mounjaro (Tirzepatide): A dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. In Q4 2023, Mounjaro generated $2.2 billion in revenue. Competitors include Ozempic (Novo Nordisk) and other GLP-1 receptor agonists.
  • Trulicity (Dulaglutide): A GLP-1 receptor agonist for the treatment of type 2 diabetes. While facing increasing competition, Trulicity remains a significant revenue generator. Competitors include Ozempic (Novo Nordisk) and Rybelsus (Novo Nordisk).
  • Verzenio (Abemaciclib): A CDK4/6 inhibitor for the treatment of certain types of breast cancer. Growing use of Verzenio and its market share is increasing, although competitors are Pfizer and Novartis.
  • Emgality (Gepants): A CGRP inhibitor for the prevention of migraines. Emgality continues to establish itself in the competitive migraine treatment market, with competition coming from other CGRP inhibitors like Aimovig and Ajovy.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and patent protection. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology.

Positioning

Eli Lilly and Company is a leading pharmaceutical company with a strong pipeline of innovative medicines. Its competitive advantage lies in its research and development capabilities, strong brands, and global presence.

Total Addressable Market (TAM)

The global pharmaceuticals market is expected to reach over $1.7 trillion by 2027. Eli Lilly and Company is positioned to capture a significant portion of this market through its diverse portfolio and innovative pipeline.

Upturn SWOT Analysis

Strengths

  • Strong R&D pipeline
  • Diverse product portfolio
  • Global presence
  • Established brand reputation
  • Experienced management team

Weaknesses

  • Patent expirations
  • High R&D costs
  • Dependence on key products
  • Exposure to litigation
  • Pricing pressures

Opportunities

  • Expansion into emerging markets
  • Development of new therapies for unmet medical needs
  • Strategic acquisitions and partnerships
  • Leveraging digital health technologies
  • Growth in personalized medicine

Threats

  • Generic competition
  • Regulatory changes
  • Economic downturns
  • Increased competition
  • Drug pricing regulations

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • PFE
  • MRK
  • NVS
  • ABBV

Competitive Landscape

Eli Lilly and Company faces competition from other large pharmaceutical companies and generic drug manufacturers. It differentiates itself through its innovative pipeline and focus on specific therapeutic areas.

Major Acquisitions

Sigilon Therapeutics

  • Year: 2023
  • Acquisition Price (USD millions): 346
  • Strategic Rationale: Sigilon's Shielded Living Therapeuticsu2122 platform technology to create cell-based therapies focused on type 1 diabetes.

Growth Trajectory and Initiatives

Historical Growth: Eli Lilly and Company has experienced solid growth in recent years, driven by new product launches and strategic acquisitions.

Future Projections: Analysts project continued revenue and earnings growth for Eli Lilly and Company, driven by its strong pipeline and increasing demand for its products.

Recent Initiatives: Recent initiatives include the launch of Mounjaro, acquisitions of smaller biotech firms, and investments in digital health technologies.

Summary

Eli Lilly is a strong pharmaceutical company with a robust pipeline and diverse product portfolio. Its financial performance is solid, and it is well-positioned for future growth. However, patent expirations and increasing competition pose potential challenges that the company needs to manage.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Eli Lilly and Company Investor Relations
  • SEC Filings
  • Analyst Reports
  • Market Research Reports
  • Company Press Releases

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and based on available information. Actual results may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Eli Lilly and Company

Exchange NYSE
Headquaters Indianapolis, IN, United States
IPO Launch date 1978-01-13
Chairman, CEO & President Mr. David A. Ricks
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 47000
Full time employees 47000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.